XML 38 R26.htm IDEA: XBRL DOCUMENT v3.22.1
SEGMENT AND ENTERPRISE-WIDE INFORMATION
 12 Months Ended
Apr. 02, 2022
Segment Reporting [Abstract]  
SEGMENT AND ENTERPRISE-WIDE INFORMATION SEGMENT AND ENTERPRISE-WIDE INFORMATION
The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker.

The Company’s reportable and operating segments are as follows:
•Plasma
•Blood Center
•Hospital

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include integration and transaction costs, deal amortization, restructuring and restructuring related costs, impairments, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”), unusual or infrequent and material litigation-related charges and gains and losses on dispositions and sale of assets. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company’s net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

Selected information by reportable segment is presented below:
(In thousands)202220212020
Net revenues
Plasma$351,945 $333,334 $460,637 
Blood Center294,541 307,370 325,661 
Hospital321,580 210,606 194,604 
Net revenues by business unit968,066 851,310 980,902 
Service (1)
20,811 20,758 19,830 
Effect of exchange rates4,319 (1,605)(12,253)
Net revenues$993,196 $870,463 $988,479 
(1) Reflects revenue for service, maintenance and parts.
(In thousands)202220212020
Segment operating income
Plasma$183,131 $172,463 $225,351 
Blood Center136,691 141,962 159,802 
Hospital129,783 84,066 80,669 
Segment operating income449,605 398,491 465,822 
  Corporate expenses (1)
(281,476)(256,751)(255,727)
  Effect of exchange rates18,993 12,830 7,920 
Deal amortization(47,414)(32,830)(25,746)
Impairment of assets and PCS2 related charges(5,732)(25,696)(75,750)
Integration and transaction costs(21,604)(18,421)(568)
Restructuring and restructuring related costs(28,824)(15,661)(19,878)
MDR and IVDR costs(11,033)(4,130)(1,506)
Litigation-related charges(1,368)(897)701 
Gains on divestitures and sale of assets9,603 32,812 8,083 
Operating income$80,750 $89,747 $103,351 
(1) Reflects shared service expenses including quality and regulatory, customer and field service, research and development, manufacturing and supply chain, as well as other corporate support functions.
(In thousands)202220212020
Depreciation and amortization
Plasma$28,314 $24,093 $63,347 
Blood Center32,489 39,672 38,429 
Hospital36,944 20,522 8,513 
Total depreciation and amortization (excluding impairment charges)$97,747 $84,287 $110,289 

(In thousands)April 2,
2022		April 3,
2021
Long-lived assets(1)
Plasma$129,241 $105,599 
Blood Center82,714 83,225 
Hospital46,527 28,735 
Total long-lived assets$258,482 $217,559 
(1) Long-lived assets are comprised of property, plant and equipment.

Selected information by operating regions is presented below:
(In thousands)April 2,
2022		April 3,
2021
Long-lived assets(1)
United States$200,927 $159,749 
Japan1,096 1,515 
Europe11,989 10,384 
Asia28,132 30,588 
Other16,338 15,323 
Total long-lived assets$258,482 $217,559 
(1) Long-lived assets are comprised of property, plant and equipment.
(In thousands)202220212020
United States$639,322 $522,607 $646,204 
Japan75,562 77,676 72,218 
Europe163,520 159,077 153,347 
Asia110,802 105,820 109,295 
Other3,990 5,283 7,415 
Net revenues$993,196 $870,463 $988,479 

Management reviews revenue based on the reportable segments noted above. Although these reportable segments are primarily product-based, they differ from the Company’s product line revenues for Plasma products and services and Blood Center products and services. Specifically, the Blood Center reportable segment includes plasma products utilized for collection in blood centers primarily for transfusion purposes. Additionally, product line revenues also include service revenues which are excluded from the reportable segments.

Net revenues by product line are as follows:
(In thousands)202220212020
Plasma products and services427,611 414,266 537,231 
Blood Center products and services236,158 239,614 252,829 
Hospital products and services329,427 216,583 198,419 
Net revenues$993,196 $870,463 $988,479